Celleron Therapeutics Ltd.   Report issue

For profit Phase 2
Founded: Oxford United Kingdom (2004)

Organization Overview

First Clinical Trial
2018
NCT03993626
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Celleron Therapeutics Ltd.

Active Ingredients

Drugs in Phase 2 Trials (3)

cxd101 (2 trials)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3